Boardroom Alpha
Boardroom Alpha
INGR · Current Report (Form 8-K) · Filed March 25, 2026

Ingredion Inc — Current Report (Form 8-K)

Form
8-K
Filed
March 25, 2026
Period
Mar 18, 2026
Ticker
INGR
Accession
0001046257-26-000113
Boardroom Alpha · Filing insights

Jason Payant named Interim CFO of Ingredion effective April 1, 2026, with $25,000 monthly interim pay.

About Ingredion Inc
Market cap
$6.4B
1Y TSR
−22.2%
3Y TSR
+2.2%
Board grade
B-
Sector
Consumer Defensive
CEO
James P Zallie
Last annual meeting: May 20, 2026 · View full Ingredion Inc profile →
ingr-20260318

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 18, 2026
 ______________________
INGREDION INCORPORATED
(Exact name of registrant as specified in its charter)
 ______________________
Delaware 1-13397 22-3514823
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
5 Westbrook Corporate Center, Westchester, Illinois
 60154
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (708) 551-2600
Not Applicable
(Former name or former address, if changed since last report)
______________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareINGRNew York Stock Exchange






Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  
 




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On March 18, 2026, the Board of Directors of Ingredion Incorporated (the “Company”) elected Jason Payant to serve as Interim Chief Financial Officer of the Company effective April 1, 2026. In this role, he will serve as the Company’s principal financial officer. Mr. Payant succeeds James D. Gray, whose resignation as Executive Vice President and Chief Financial Officer of the Company effective March 31, 2026 was reported on January 27, 2026.
Mr. Payant, age 55, has been in service with the Company since 2012 in roles of increasing responsibility. He has served as the Company’s Vice President, Finance, Global Texture & Healthful Solutions since November 2025, in which position he will continue during his service as Interim Chief Financial Officer. Before his appointment to this position, Mr. Payant was Vice President, Finance, Food & Industrial Ingredients U.S./Canada from January 2024 to November 2025, Interim Vice President, Investor Relations from September 2021 to October 2022, and Vice President, Finance from October 2017 to January 2024.
There are no arrangements or understandings between Mr. Payant and any other persons pursuant to which Mr. Payant was selected as Interim Chief Financial Officer. In addition, there have been no transactions, nor are there any currently proposed transactions, to which the Company was, is or is to be a participant and in which Mr. Payant or any member of his immediate family had, has or will have, a direct or indirect material interest.
During the period of his service as the Company’s Interim Chief Financial Officer, Mr. Payant will receive monthly cash compensation of $25,000 in addition to his pre-existing compensation and benefits.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 25, 2026  Ingredion Incorporated
  By: /s/ Tanya M. Jaeger de Foras
   
Tanya M. Jaeger de Foras
 Senior Vice President, Chief Legal Officer,
 Corporate Secretary, and Chief Compliance Officer
   

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Ingredion Inc (INGR)

Reference

Frequently asked questions

When did Ingredion Inc file this 8-K?
Ingredion Inc (INGR) filed this Current Report (Form 8-K) with the SEC on March 25, 2026. The accession number assigned by EDGAR is 0001046257-26-000113.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Jason Payant named Interim CFO of Ingredion effective April 1, 2026, with $25,000 monthly interim pay. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Ingredion Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Ingredion Inc has filed under CIK 1046257, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer